Oxygen–Ozone Therapy Associated with Alpha Lipoic Acid Plus Palmitoylethanolamide and Myrrh versus Ozone Therapy in the Combined Treatment of Sciatic Pain Due to Herniated Discs: Observational Study on 318 Patients

Bonetti, Matteo; Lauritano, D; Ottaviani, Gian Maria; Fontana, Alessandro; Zambello, Alessio; Gatta, Luigi; Muto, Mario

doi:10.3390/ijerph19095716

Cited by 6 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings confirm the results of Bonetti et al [25] regarding the therapeutic efficacy and the duration of the effect of alpha lipoic acid + palmitoylethanolamide and myrrh associated with ozone therapy. Additionally, we found that the combined effect of this association is more effective than the sole treatment by steroid, allowing better pain control, especially in the later stages of the disease.…”

Section: Discussionsupporting

confidence: 92%

“…The possibility to orally combine alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh with guided oxygen-ozone CT infiltration has been documented to be effective in further improving the clinical outcome. In a recent study, this association has been assessed and the authors concluded that it "can be considered an excellent therapeutic solution, improving the good final clinical result with better control of symptoms, particularly in the first phase of the disease" [25]. However, in that study, the necessity of further investigating the therapeutic effects of alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh with guided oxygen-ozone CT infiltration was underlined.…”

Section: Introductionmentioning

confidence: 99%

“…In light of these considerations, we, therefore, decided to further evaluate the therapeutic results in a group of 246 patients treated with CT-guided infiltrations of oxygen-ozone associated with alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh. What led us to associate the therapies in this study was the need to investigate in more depth the enhancement that they bring to the analgesic and anti-inflammatory actions of oxygenozone therapy alone, together with the greater maintenance of its clinical results over time, as suggested by the literature [25].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

New Approach to Chronic Back Pain Treatment: A Case Control Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background and objective: Our study compares the clinical outcome of chronic low back pain present for over six months treated with alpha-lipoic acid (ALA) + palmitoylethanolamide (PEA) and myrrh and periradicular infiltrations of oxygen-ozone under CT guide to periradicular steroidal infiltrations in a short (one week), medium (three months) and long-term period (six months). Methods: We enrolled 246 patients (Group A) with low back pain treated with periradicular infiltrations of oxygen-ozone under CT guide combined with 800 mg/day of ALA + 600 mg/day of PEA + 200 mg/day of myrrh orally. Group B consisted of 176 patients with low back pain treated with periradicular infiltrations of steroids. Patients were clinically monitored one week after the end of treatment, at three months, and at six months using a modified version of McNab’s method. Results: In Group A, the one-week clinical follow-up registered a complete remission of painful symptoms in 206 patients (83.7%), and this manifestation remained optimal in 191 patients at the three-month follow-up (77.6%) and in 178 at six months (72.3%). While the results were satisfactory in 28 patients (10.9%) at one week, 32 (13%) in the medium term, and 41 (16.6%) in the long term, non-significant results were found in 12 patients in the control at one week (4.6%), in 23 at three months (9.3%) and in 27 at six months (10.9%). In Group B, at the short-term follow-up we obtained an excellent clinical result in 103 patients (80.5%), while at three months 85 patients reported the persistence of clinical benefit (66.4%) and at six months, 72 (56.2%) reported the same result. The result was rated satisfactory in 11 (8.5%) and poor in 4 (3%). At the three-month follow-up, 23 (18%) reported a satisfactory result, and 20 (15.6%) had a poor result. At six months, 24 (18.8%) reported the persistence of a satisfactory result while for 32 the result was poor (25%). Conclusion: The results highlight how the treatment associated with ozone therapy and oral administration of alpha-lipoic acid + palmitoylethanolamide and myrrh can be considered a valid alternative to common therapeutic approaches in the treatment of chronic low back pain.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

New Approach to Chronic Back Pain Treatment: A Case Control Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Применение антиоксидантной терапии, в том числе АЛК, в лечении компрессионной радикулопатии имеет множество примеров [76][77][78]. В проспективном обсервационном исследовании оценивалась эффективность реабилитации молодых пациентов (n = 128) с дискогенной радикулопатией.…”

Section: компрессионные радикулопатииunclassified

Modern view on the use of alpha lipoic acid in neurological practice

Khaibullina,

Maksimov,

Khaibullina

2024

Medicinskij sovet

View full text Add to dashboard Cite

Alpha lipoic acid (ALA) is an essential cofactor for mitochondrial enzymes, a powerful antioxidant, and an important component of many metabolic processes. Most research on ALA has focused specifically on its antioxidant properties. A number of conditions – aging, atherosclerosis, liver cirrhosis, diabetes mellitus, various types of polyneuropathy, psoriasis and others can significantly reduce the level of ALA in the body. The article analyzes modern literature (107 sources, including 17 systematic reviews and meta-analyses). Traditionally, ALA is used in complex therapy of patients suffering from diabetic and alcoholic polyneuropathy. However, the analysis of studies conducted around the world is not limited to these two nosological forms. The use of ALA as adjuvant therapy for a number of conditions and diseases is justified, as confirmed by clinical studies, systematic reviews and meta-analyses. All studies assessed not only the effectiveness of ALC, but also its safety and the incidence of adverse events and showed that ALC has a high safety profile. ALA has not only a pronounced antioxidant effect, but also the ability to chelate toxic metals, increase intracellular glutathione levels, reduce blood glucose levels, overcome insulin resistance, participate in mitochondrial metabolism, stimulate the production of cAMP, normalize the lipid profile, reduce the level of inflammatory markers, etc. Based on Because of the positive effect of using ALC in the treatment of various symptoms and nosologies, the list of indications requires revision, expansion and addition.

show abstract

“…Among the studies meeting all the inclusion criteria, two were double-blinded RCTs [103,104], and only one of them [103] was based on a sample power calculation. The other eight studies [65,95,[105][106][107][108][109][110] were observational and open-label studies. A total of 1116 patients treated with PEA and its derivatives included in the data synthesis suffered from all conditions associated with resistant chronic pain.…”

Section: Synthesis Of the Studiesmentioning

confidence: 99%

Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence

et al. 2022

View full text Add to dashboard Cite

Some 30–50% of the global population and almost 20% of the European population actually suffer from chronic pain, which presents a tremendous burden to society when this pain turns into a disability and hospitalization. Palmitoylethanolamide (PEA) has been demonstrated to improve pain in preclinical contexts, but an appraisal of clinical evidence is still lacking. The present study aimed at addressing the working hypothesis for the efficacy of PEA for nociceptive musculoskeletal and neuropathic pain in the clinical setting. The systematic search, selection and analysis were performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 recommendations. The primary outcome was pain reduction, as measured by a pain assessment scale. The secondary outcome was improvement in quality of life and/or of parameters of function. The results obtained for a total of 933 patients demonstrate the efficacy of PEA over the control (p < 0.00001), in particular in six studies apart from the two randomized, double-blind clinical trials included. However, the results are downgraded due to the high heterogeneity of the studies (I2 = 99%), and the funnel plot suggests publication bias. Efficacy in achieving a reduction in the need for rescue medications and improvement in functioning, neuropathic symptoms and quality of life are reported. Therefore, adequately powered randomized, double-blind clinical trials are needed to deepen the domains of efficacy of add-on therapy with PEA for chronic pain. PROSPERO registration: CRD42022314395.

show abstract

Oxygen–Ozone Therapy Associated with Alpha Lipoic Acid Plus Palmitoylethanolamide and Myrrh versus Ozone Therapy in the Combined Treatment of Sciatic Pain Due to Herniated Discs: Observational Study on 318 Patients

Cited by 6 publications

References 37 publications

New Approach to Chronic Back Pain Treatment: A Case Control Study

New Approach to Chronic Back Pain Treatment: A Case Control Study

Modern view on the use of alpha lipoic acid in neurological practice

Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence

Contact Info

Product

Resources

About